mRNA Length Analysis Service
Overview
In the architecture of messenger RNA (mRNA) therapeutics, the precise length of the transcript is a foundational critical quality attribute (CQA). The presence of truncated species (shortmers) or unintended read-through products (longmers) can drastically alter the translational efficiency, stability, and safety profile of the drug substance. CD BioGlyco provides an industry-leading mRNA length analysis service that delivers high-resolution mapping of the entire molecular weight distribution of your RNA constructs. By utilizing advanced capillary electrophoresis and chromatographic techniques, we distinguish between full-length transcripts and nearly-identical impurities that standard analytical tools often fail to resolve. Our platform is designed to support the rigorous demands of vaccine development, gene editing, and protein replacement therapies.
Core Technologies
To achieve the high fidelity required for therapeutic validation, CD BioGlyco employs a multi-platform approach that overcomes the inherent challenges of large, structured RNA molecules.
- Capillary Gel Electrophoresis (CGE-LIF)
Utilizing optimized sieving matrices such as high-concentration polyvinylpyrrolidone (PVP), our CGE-LIF platform provides exceptional resolution for mRNA chain-length distribution, effectively separating full-length species from degraded fragments or incomplete transcripts.
- Ion-Pair Reversed-Phase Liquid Chromatography (IP-RP LC)
This technique offers a high-resolution orthogonal method to assess mRNA length based on hydrophobicity and size, particularly useful for characterizing the purity of shorter and medium-length transcripts.
- Size Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS)
We provide absolute molecular weight determination, allowing for the characterization of mRNA in its native or denatured state without the need for reference standards.
- Mass Photometry
For rapid screening, we utilize single-molecule imaging to measure the mass distribution of mRNA populations, identifying the presence of aggregates or significant length variations in a label-free environment.
- Integrated Poly(A) Tail Analysis
Leveraging enzymatic cleavage (RNase T1) followed by liquid chromatography, we provide detailed insights into the length and heterogeneity of the poly(A) tail, which is critical for mRNA half-life.
Define the Length. Secure the Effect.
Our service is designed to cover the entire lifecycle of mRNA development, from early discovery to late-stage quality control.
- Full-length mRNA integrity mapping: Quantitative assessment of the percentage of intact, target-length transcripts in a given batch.
- Truncated species quantification: Identification and measurement of incomplete transcripts resulting from premature termination of in vitro transcription (IVT).
- Read-through (Longmer) analysis: Detection of unintended extensions of the mRNA sequence caused by inefficient transcription termination.
- Poly(A) tail length profiling: Specific measurement of the 3' tail length distribution, which is essential for predicting in vivo protein expression duration.
- Self-amplifying RNA (saRNA) sizing: Specialized protocols for the characterization of extremely large RNA molecules (9kb to 15kb) that exceed the capacity of standard electrophoresis.
- Batch-to-batch comparability studies: Statistical comparison of length distributions across multiple manufacturing runs to ensure consistency.
- IVT process optimization feedback: Using length analysis as a readout to refine DNA template design or transcription conditions for improved transcript fidelity.
Workflow
Sample Stabilization and Quantification
Upon arrival, each mRNA sample undergoes immediate stabilization in certified RNase-free buffers to prevent any degradation prior to analysis. We perform a dual verification of sample concentration and purity using fluorometric assays (e.g., Qubit) and spectrophotometry. This initial quality control ensures the starting material meets the stringent requirements for high-resolution length mapping, confirming that the sample is within the optimal detection range and free of contaminants that could interfere with subsequent analysis.
Advanced Denaturation Processing
Therapeutic mRNA molecules frequently adopt complex secondary and tertiary structures that can mask their true length during electrophoresis. To overcome this, we apply a rigorous denaturation protocol involving precise thermal cycling in the presence of high-purity formamide and urea. This process effectively eliminates all intramolecular base pairing, ensuring each mRNA molecule is maintained in a linear, single-stranded conformation throughout the separation process, which is critical for accurate size determination.
High-Resolution Separation and Calibration
Samples are analyzed using our premier capillary gel electrophoresis with CGE-LIF or IP-RP LC platforms. Each run is calibrated against a suite of RNA ladders and internal standards with precisely defined lengths. This calibration translates migration time or retention volume directly into nucleotide count, enabling exceptional resolution capable of distinguishing size variants differing by less than 100 nucleotides, even for transcripts exceeding 10 kb.
Chain-Length Distribution Profiling
Following separation, our proprietary software algorithms perform advanced peak deconvolution and integration on the resulting electropherograms or chromatograms. This allows for the precise identification and quantification of the full-length mRNA peak relative to the "shortmer" (degradation/truncation) and "longmer" (incomplete transcription/aggregate) populations. We calculate critical parameters such as the polydispersity index (PDI) to quantify sample heterogeneity and map specific degradation patterns (e.g., 5'- vs. 3'-end bias).
Technical Data Integration and Functional Correlation
The raw length distribution data is synthesized and interpreted within a broader biological context. Our reports go beyond simple percentages by integrating your integrity results with empirical "published data" on translational efficiency. This correlation provides a functional perspective on how the observed molecular weight distribution may impact protein yield and overall therapeutic performance, turning analytical data into actionable developmental insights.
Expert Consultation and Reporting
Every project culminates in the delivery of a comprehensive analytical dossier and a consultative review session. The dossier includes all methodological details, raw data, calibrated electropherograms/chromatograms, and a summary of critical quality attributes. More importantly, our PhD-level specialists meet with your team to discuss the implications of the findings, offering expert guidance on optimizing IVT reactions, improving formulation stability, or addressing specific questions for pre-clinical and regulatory documentation.
Publication Data
Journal: Genome biology
DOI: 10.1186/s13059-018-1418-0
IF: 16.3
Published: 2018
Results: In this groundbreaking study, Anvar et al. employ full-length mRNA sequencing using PacBio's single-molecule long-read technology to comprehensively investigate the coordination between transcription initiation and mRNA processing events in the MCF-7 breast cancer cell line and human primary tissues. The research uncovers widespread interdependence between alternative transcription start sites (TSSs), splicing, and polyadenylation site (PAS) usage, revealing that these processes are tightly coupled on a single-molecule level, which significantly restricts the transcriptome's combinatorial complexity. By analyzing thousands of genes, the authors demonstrate that the choice of a TSS can influence splicing patterns and PAS selection, even over long genomic distances, challenging the notion of these as independent events. The study further validates key coupling events using Sanger sequencing and single-molecule RNA FISH, confirming the co-occurrence of specific features on individual mRNA molecules. Additionally, by integrating the full-length transcriptome data with shotgun proteomics, the authors predict and provide evidence for the translation of novel open reading frames, thereby linking transcriptional coordination to the proteomic landscape. This work fundamentally advances our understanding of gene regulation by demonstrating that transcription initiation and mRNA processing are functionally interconnected, providing a critical resource for future studies on transcriptome complexity and regulation.
Applications
Ex Vivo Cell Engineering
Monitoring the quality of mRNA used for the production of CAR-T cells, where the presence of shortmers can reduce transfection efficiency and the overall therapeutic window of the engineered cells.
Therapeutic Protein Production
Validating the consistency of mRNA constructs used in protein replacement therapies, where the maintenance of a specific poly(A) tail length distribution is vital for sustained therapeutic effect.
Rare Disease Drug Discovery
Supporting the development of orphan drugs by providing the high-resolution structural data required to optimize the IVT process for complex or non-standard mRNA sequences.
RNA Stability and Stress Testing
Assessing how various storage conditions and environmental stressors impact the molecular weight distribution of mRNA over time, aiding in the determination of optimal shelf-life.
Advantages
Absolute Mass Determination
By integrating SEC with MALS technology, we provide the absolute molecular weight of your mRNA constructs, eliminating the inaccuracies associated with relative sizing against potentially mismatched RNA standards.
Rigorous Denaturation Protocols
Our specialized buffers and temperature-controlled separation environments prevent the re-annealing of complex secondary structures, ensuring that every peak in the electropherogram represents a true length variation rather than a conformational artifact.
High-Sensitivity Detection
Our LIF systems allow for the detection of trace-level shortmer impurities that are often invisible to UV-based detectors, providing a more conservative and safer assessment of product purity.
Customizable Analytical Matrices
We offer flexible separation parameters, adjusting voltage, temperature, and buffer concentration to provide the highest possible resolution for your specific mRNA length range, whether it is 1,000 or 12,000 nucleotides.
Frequently Asked Questions
Customer Review
The resolution CD BioGlyco achieved with our 8kb saRNA was remarkable. They successfully identified a 5% shortmer contamination that our internal assays had completely missed.
— By Dr. J.P., Senior Scientist, Immunology Department
CD BioGlyco's length analysis has become a standard part of our batch-release protocol. Their data is consistently high-quality, and the reports are perfectly formatted for our regulatory filings.
— By Manager of Quality Control, Biopharma Group
Speed and accuracy are vital for our personalized vaccine program. CD BioGlyco delivered comprehensive length profiles for 20 different constructs in less than a week, allowing us to stay on schedule.
— By Dr. L. Chen, Director of R&D
Associated Services
mRNA Biodistribution Analysis Service
Track the systemic and local distribution of your mRNA therapeutics post-administration to ensure target-specific delivery.
T Cell Cytokine Secretion Analysis Service
Evaluate the immune response to mRNA vaccines by measuring precise cytokine profiles in stimulated T cells.
Antibody Titer and Specificity Analysis Service
Quantify the humoral immune response and the binding affinity of antibodies generated by mRNA-encoded antigens.
Neutralizing Antibody Assay Service
Assess the functional potency of the antibodies induced by your mRNA vaccine in neutralizing target pathogens.
CD BioGlyco is your strategic partner in ensuring the molecular integrity and therapeutic potential of mRNA products. Our mRNA length analysis service provides the critical data needed to navigate the complexities of RNA characterization with confidence. Whether you are optimizing a discovery-phase construct or validating a commercial manufacturing process, our team of experts is ready to support your journey from sequence to success, contact us!
Reference
- Anvar, S.Y.; et al. Full-length mRNA sequencing uncovers a widespread coupling between transcription initiation and mRNA processing. Genome biology. 2018, 19(1): 46. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform